Excited to share that TD2 will be presenting three groundbreaking posters at the upcoming AACR meeting in April! 🌟 Join us to learn more about the latest advancements at TD2: https://hubs.li/Q02q8hnz0 Innovations in Glioblastoma Research - Discover our strides in utilizing PDX models integrated with patient history and whole exome sequencing to enhance preclinical studies. Combating KRAS/LKB1 Mutant Lung Cancer - Learn about our breakthroughs in epigenetic-based combination therapy showing promise against this challenging condition. Advancing Cell Cycle Inhibitor Studies - Explore our insights from the flow cytometry evaluation of cell cycle arrest in NSCLC cells following treatment with novel inhibitors. These studies underscore our commitment to advancing cancer research through innovative and translational approaches. For detailed insights into our findings and to connect with our team, visit https://hubs.li/Q02q8hnz0. Don't miss this opportunity to engage with us and learn more about our work in transforming cancer treatment. #AACR2024 #OncologyResearch #CancerResearch
Translational Drug Development (TD2)’s Post
More Relevant Posts
-
Ovarian cancer affects hundreds of thousands of women around the world, to the extent of nearly 7 cases per 100,000. That's why Wistar researchers like Executive Vice President Dr. David Weiner are working on the basis of next-generation therapeutics to fight ovarian cancer with the power of basic biomedical research. By engineering novel monoclonal antibodies to engage the immune system's natural killer cells against ovarian cancer — a feat achieved by taking advantage of the siglec-7 receptor in collaboration with Wistar's Abdel-Mohsen laboratory — Dr. Weiner's team has demonstrated preclinical efficacy against ovarian cancer tumors. Read more about how Drs. David Weiner and Mohamed Abdel-Mohsen joined forces to make their ovarian-cancer-fighting discovery here: https://bit.ly/3QCdYs9 #worldovariancancerday #ovariancancerday #ovariancancer #cancerresearch
To view or add a comment, sign in
-
Tumoroid cultures, also known as tumor organoids, are three-dimensional cell culture models that closely mimic the complexity and characteristics of actual tumors. These cultures have the potential to revolutionize various areas of cancer research and treatment by providing more accurate and personalized models for studying tumor biology, drug discovery, and treatment development. Looking forward to this webinar!
🧫 Interested in patient-derived cancer organoids for drug screening and development? 🎥 Don’t miss this two-part webinar that dives into the latest developments in cancer organoid (tumoroid) technology & its potential implications for drug screening. https://lnkd.in/gR3iTyKb Register now to: 👉 Learn about establishing tumoroid models for cancer research using patient derived tumor cells 👉 Discover tips and tricks to optimize these advanced tumoroid models for large-scale studies and functional assay development 👉 Learn about breast cancer disease modeling to uncover therapeutic targets to combat advanced breast cancer 👉 Speak with an expert cancer cell biologist in a live Q&A session Reserve your spot today! https://lnkd.in/gR3iTyKb #CancerResearch #DrugScreening #3DCancerCulture #OncoPro
To view or add a comment, sign in
-
🚀 Exciting Clinical Milestone for Eisbach Bio! 🚀 We are thrilled to announce that the first patient has been dosed in our Phase 1/2 MATCH clinical trial of EIS-12656. The cancer trial conducted at The University of Texas MD Anderson Cancer Center, marks a significant step forward in our mission to develop transformative medicines leveraging synthetic lethality. “Our entry into the cancer clinic with the allosteric inhibitor EIS-12656 represents a unique approach in targeting ALC1, offering hope for patients with tumors characterized by impaired DNA damage and repair,” said Adrian Schomburg, Ph.D., Founder and CEO of Eisbach Bio GmbH. “This clinical study will explore EIS-12656’s potential to target specific genetic and molecular vulnerabilities, aiming to deliver a drug that is both efficacious and well-tolerated.” Full press release: https://lnkd.in/eTC65FeW Stay tuned for more updates as we continue our journey to pioneer the frontiers of cancer therapy. 💪 #CancerResearch #ClinicalTrials #Biotechnology #Oncology #SyntheticLethality
To view or add a comment, sign in
-
#MovingMedicineForward: Congratulations to our friends at #EisbachBio on dosing the first patient in their Phase 1/2 MATCH clinical trial for EIS-12656, a new allosteric inhibitor targeting genetically-defined advanced solid tumors. This study aims to evaluate the safety, tolerability, & efficacy of EIS-12656, with a focus on #Gynecological, #Pancreatic, & #Prostate cancer patients progressing under PARP inhibitor treatment. At CTI, we're proud to collaborate with Eisbach Bio in providing #Regulatory & #ClinicalTrial management services for this #Oncology trial. Together, we’re #AdvancingHealthcareSolutions for those battling advanced cancers. Learn more about this trial in the link below.
🚀 Exciting Clinical Milestone for Eisbach Bio! 🚀 We are thrilled to announce that the first patient has been dosed in our Phase 1/2 MATCH clinical trial of EIS-12656. The cancer trial conducted at The University of Texas MD Anderson Cancer Center, marks a significant step forward in our mission to develop transformative medicines leveraging synthetic lethality. “Our entry into the cancer clinic with the allosteric inhibitor EIS-12656 represents a unique approach in targeting ALC1, offering hope for patients with tumors characterized by impaired DNA damage and repair,” said Adrian Schomburg, Ph.D., Founder and CEO of Eisbach Bio GmbH. “This clinical study will explore EIS-12656’s potential to target specific genetic and molecular vulnerabilities, aiming to deliver a drug that is both efficacious and well-tolerated.” Full press release: https://lnkd.in/eTC65FeW Stay tuned for more updates as we continue our journey to pioneer the frontiers of cancer therapy. 💪 #CancerResearch #ClinicalTrials #Biotechnology #Oncology #SyntheticLethality
To view or add a comment, sign in
-
🔬 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐱 𝐄𝐒𝐌𝐎 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝟐𝟎𝟐𝟒 We look forward to presenting updates for selected assets of our diversified immuno-oncology portfolio at the ESMO - European Society for Medical Oncology Congress 2024 in Barcelona. This year’s presentations feature programs across our multi-platform #oncology toolkit, including #mRNA-based cancer vaccines, targeted therapy approaches such as CAR-T cell therapies and ADCs, and next-generation #immunomodulators. We believe that the future of cancer treatment will be driven by the combination of modalities. Combination therapies have the potential to open up new opportunities through complementary or even synergistic mechanisms of action. Our goal is clear: Establish novel treatment paradigms to address the fundamental challenges of treating #cancer across all stages of the disease and improve outcomes for patients. 🚀 𝐅𝐢𝐧𝐝 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐭𝐨 𝐛𝐞 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐚𝐭 #𝐄𝐒𝐌𝐎𝟐𝟒. 👇 𝑹𝒆𝒂𝒅 𝒎𝒐𝒓𝒆: https://lnkd.in/etszNHB8
To view or add a comment, sign in
-
Inocras CancerVision demonstrates 100% concordance with Illumina’s TSO500 panel—meaning we detect every single variant identified by TSO500, without missing a thing. But CancerVision goes beyond, offering additional insights that only a whole-genome sequencing approach can deliver. This marks a significant leap in comprehensive cancer genomics. #CancerGenomics #WholeGenomeSequencing #PersonalizedMedicine #CancerResearch #OncologyInnovation #PrecisionOncology #CancerDiagnostics #Bioinformatics #ClinicalGenomics #CancerVision #Inocras
We're excited to share the significant findings from the recently published CancerVision Target-Enhanced Whole-Genome Sequencing (TE-WGS) study. From a cohort of 49 patients, our CancerVision TE-WGS test detected all 498 variants identified by Illumina’s TSO500 panel, solidifying our technology’s precision as a comprehensive approach in personalized oncology that matches TSO500's key biomarker detection capabilities. CancerVision offers additional, critical clinical actions, and its adaptability and cost-effectiveness underscore its clinical utility in personalized cancer treatment. To read the abstract, visit more: https://lnkd.in/gMAGJyvQ
To view or add a comment, sign in
-
👏 Thank you James Clubb for giving an excellent presentation on our promising clinical data on TILT-123 in combination with pembrolizumab for #OvarianCancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 this week in San Diego! James demonstrated our phase 1 trial’s promising preliminary safety and efficacy results for platinum-resistant or refractory ovarian cancer patients, which highlight the potential of TILT-123 as an innovative cancer treatment by altering the tumor microenvironment and bolstering the body's immune response against cancer. We were delighted to see this included by Drug Discovery World in their highlights from #AACR24 piece: https://lnkd.in/e8-2kX36 📝 See the poster: https://lnkd.in/gHguit5C 🔗 Read our press release: https://lnkd.in/gewF3uTn #BioTech #Innovation #Oncology #ClinicalTrial
To view or add a comment, sign in
-
We're excited to share the significant findings from the recently published CancerVision Target-Enhanced Whole-Genome Sequencing (TE-WGS) study. From a cohort of 49 patients, our CancerVision TE-WGS test detected all 498 variants identified by Illumina’s TSO500 panel, solidifying our technology’s precision as a comprehensive approach in personalized oncology that matches TSO500's key biomarker detection capabilities. CancerVision offers additional, critical clinical actions, and its adaptability and cost-effectiveness underscore its clinical utility in personalized cancer treatment. To read the abstract, visit more: https://lnkd.in/gMAGJyvQ
To view or add a comment, sign in
-
Hope can go a long way. And for cancer patients and researchers, immuno-oncology is promising. Download our white paper to learn about the evolution of understanding cancer and where we are today with immunotherapies: https://bit.ly/4aICiku #DrugDevelopment #Oncology #ImmunoOncology #CancerResearch
To view or add a comment, sign in
-
🔊 This September, during Prostate Cancer Awareness Month, Heidelberg Pharma AG stands in solidarity with the millions of men and their families affected by #ProstateCancer. Prostate cancer is the most common cancer in men, with cases expected to nearly double by 2040. At #HeidelbergPharma, our mission is to create inspired medicines for those diagnosed with this serious disease to enhance treatment options and survival rate. Our preclinical candidate, HDP-103, a PSMA-ATAC, is specifically designed to target metastatic castration-resistant prostate cancer - a particularly challenging form of the disease. 🔊 Collectively, we can make a difference in the fight against prostate cancer! #ADCs #ATAC #ProstateCancerMonth #CancerResearch
To view or add a comment, sign in
10,650 followers